Treatment of non-alcoholic fatty liver disease

The effect of genistein supplementation on glycemic state, insulin resistance and adipose tissue in non alcoholic fatty liver patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201506222480N6

Enrollment

100

Registered

2015-07-12

Start date

2015-07-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: wheat starch in capsule once a day for 8 weeks. Intervention 2: 250 mg genistein as capsule once per day for 8 weeks.

Placebo

Treatment - Drugs

wheat starch in capsule once a day for 8 weeks

250 mg genistein as capsule once per day for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Volunteers whom their fatty liver were confirmed by ultrasonography; Don't have any Acute or chronic disease of the liver or bile ducts Exclusion criteria: Severe weight loss or gain; Pregnancy; ALT serum level 10 times more than normal range.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Insulin. Timepoint: Before intervention and two months after intervention inception. Method of measurement: By serum analysis.;FBS. Timepoint: Before intervention and two months after intervention inception. Method of measurement: By serum analysis.;Fat mass. Timepoint: Before intervention and two months after intervention inception. Method of measurement: By BIA device.	—

Secondary

Measure	Time frame
HOMA-IR. Timepoint: Before and two months after intervention inception. Method of measurement: Calculate by HOMA index equation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSasan Amanat

Shiraz University of Medical Sciences

snatm69@gmail.com+98 717251008

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026